LCM
TVTX icon

Legato Capital Management’s Travere Therapeutics TVTX Stock Holding History

Legato Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99M Buy
87,833
+23,723
+37% +$1.05M 0.41% 42
2026
Q1 		$1.9M Sell
64,110
-23,426
-27% -$700K 0.17% 175
2025
Q4 		$3.34M Buy
87,536
+16,506
+23% +$537K 0.29% 70
2025
Q3 		$1.7M Buy
+71,030
New +$1.34M 0.18% 161
2025
Q2 		– Sell
-32,731
Closed -$587K – 627
2025
Q1 		$587K Buy
+32,731
New +$664K 0.08% 393

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Legato Capital Management's TVTX Position: Q2 2026 in Review

Legato Capital Management increased its Travere Therapeutics (TVTX) stake by 37% in Q2 2026, buying an estimated $1.05M and bringing the position to 87,833 shares worth $4.99M. The position accounts for 0.41% of the portfolio, ranked #42.

Legato Capital Management first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Legato Capital Management held 87,833 shares of Travere Therapeutics worth $4.99M as of Q2 2026.
  • Legato Capital Management bought 23,723 Travere Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Travere Therapeutics made up 0.41% of Legato Capital Management's portfolio in Q2 2026, its #42 holding.
  • Legato Capital Management first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.